Ophthalmic Business News

The top pieces of news in ophthalmology in December include acquisitions and FDA clearances.

Belkin Vision has been selected to receive 17.5 million euros in grants and equity from the European Innovation Council Accelerator to aid in the development of its glaucoma laser, according to a company press release.

Novartis is set to acquire Gyroscope Therapeutics in a deal that could be worth up to $1.5 billion, according to press releases from both companies.

The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.

The first patients have been dosed in the phase 2/3 Sirius and Celeste clinical trials investigating QR-421a in patients with USH2A mediated retinitis pigmentosa and Usher syndrome, according to a press release from ProQR Therapeutics.

Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.

Raj Kannan has been appointed as CEO of Aerie Pharmaceuticals, effective Dec. 20, according to a company press release.

The first patient in the Chinese portion of the Denali phase 3 clinical trial, investigating NCX 470 in patients with open-angle glaucoma or ocular hypertension, has been screened, according to a press release from Nicox.

Aramis Biosciences has launched following the completion of Series A financing totaling $10.5 million, according to a press release.

Iacta Pharmaceuticals and Tallc will enter into a strategic collaboration and licensing agreement to implement Tallc’s SmartCelle technology in clinical development, according to a press release from the companies.